| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| phenytoin sodium | Injection, solution | 250 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| codeine phosphate hemihydrate | Oral Liquid, solution | 5 mg/mL | Current | Unavailable | Manufacturing | 28/11/2025 |
| topiramate | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| midazolam | Injection, solution | 5 mg/mL | Current | Limited Availability | Manufacturing | 28/11/2025 |
| metformin hydrochloride | Tablet, film coated | 500 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| olanzapine | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| olanzapine | Tablet, film coated | 7.5 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| donepezil hydrochloride | Tablet, film coated | 5 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| lamivudine | Tablet, film coated | 300 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| levetiracetam | Tablet, film coated | 1000 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| sildenafil citrate | Tablet, film coated | 140.45 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 28/11/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Current | Limited Availability | Manufacturing | 28/11/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| indapamide hemihydrate | Tablet, sugar coated | 2.5 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 28/11/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 28/11/2025 |
| finasteride | Tablet, film coated | 1 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| nystatin | Oral Liquid, suspension | 100000 IU/mL | Resolved | Available | Unexpected increase in consumer demand | 28/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 28/11/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 28/11/2025 |
| lamotrigine | Tablet, uncoated | 25 mg | Current | Limited Availability | Commercial Changes / Commercial viability | 28/11/2025 |
| cyproterone acetate | Tablet, uncoated | 100 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| tobramycin | Inhalation, conventional | 60 mg/mL | Anticipated | Available | Manufacturing | 28/11/2025 |
| nizatidine | Capsule, hard | 150 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| Semaglutide | Injection, solution | 1.34 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 28/11/2025 |
| prasugrel | Tablet, film coated | 5 mg | Current | Unavailable | Commercial Changes / Commercial viability | 28/11/2025 |
| lanreotide acetate | Injection, solution | 100 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 28/11/2025 |
| naltrexone hydrochloride | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 28/11/2025 |
| levothyroxine sodium | Tablet | 200 microgram | Resolved | Available | Unexpected increase in consumer demand | 28/11/2025 |
| atracurium besilate | Injection, solution | 10 mg/mL | Anticipated | Available | Manufacturing | 28/11/2025 |
| mivacurium chloride | Injection, solution | 2.14 mg/mL | Current | Unavailable | Manufacturing | 28/11/2025 |
| framycetin sulfate~gramicidin~dexamethasone | Ear Drops | 5 mg/mL~.05 mg/mL~.5 mg/mL | Anticipated | Available | Manufacturing | 28/11/2025 |
| phenytoin sodium | Injection, solution | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 28/11/2025 |
| phenytoin sodium | Injection, solution | 250 mg | Current | Limited Availability | Manufacturing | 28/11/2025 |
| cisatracurium besilate | Injection, solution | 6.7 mg/mL | Anticipated | Available | Manufacturing | 28/11/2025 |
| naratriptan hydrochloride | Tablet, film coated | 2.78 mg | Current | Limited Availability | Manufacturing | 28/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet, uncoated | 1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 28/11/2025 |
| valaciclovir hydrochloride | Tablet, film coated | 1112 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| risperidone | Injection, modified release | 50 mg | Resolved | Available | Manufacturing | 28/11/2025 |
| verapamil hydrochloride | Tablet, modified release | 240 mg | Resolved | Available | Manufacturing | 27/11/2025 |
| glimepiride | Tablet, uncoated | 2 mg | Anticipated | Available | Manufacturing | 27/11/2025 |
| acetazolamide sodium | Injection, powder for | 549.5 mg | Current | Unavailable | Manufacturing | 27/11/2025 |
| pentetic acid | Injection, powder for | 5 mg | Current | Unavailable | Manufacturing | 27/11/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| risperidone | Tablet, film coated | 2 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Resolved | Available | Manufacturing | 27/11/2025 |
| bisoprolol fumarate | Tablet | 2.5 mg | Current | Unavailable | Manufacturing | 27/11/2025 |
| bisoprolol fumarate | Tablet | 10 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| levetiracetam | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 7.5 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| cobicistat~atazanavir | Tablet, film coated | 150 mg~300 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| risperidone | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 27/11/2025 |
| risperidone | Tablet, film coated | 2 mg | Anticipated | Available | Manufacturing | 27/11/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Resolved | Available | Manufacturing | 27/11/2025 |
| paclitaxel | Injection, powder for | 100 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, hard | 40 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, hard | 20 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, hard | 30 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, hard | 10 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, hard | 60 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 27/11/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Unavailable | Manufacturing | 27/11/2025 |
| lamotrigine | Tablet, dispersible | 100 mg | Current | Limited Availability | Manufacturing | 27/11/2025 |
| lamotrigine | Tablet, dispersible | 200 mg | Current | Unavailable | Manufacturing | 27/11/2025 |
| verapamil hydrochloride | Tablet, film coated | 240 mg | Current | Limited Availability | Manufacturing | 26/11/2025 |
| valaciclovir | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 26/11/2025 |
| sodium pyrophosphate | Injection, powder for | 30 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| risperidone | Tablet | 1 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 26/11/2025 |
| losartan potassium | Tablet, film coated | 50 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| losartan potassium | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| mycophenolate mofetil | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 26/11/2025 |
| nystatin | Oral Liquid | 100000 IU/mL | Resolved | Available | Commercial Changes / Commercial viability | 26/11/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| amlodipine besilate~atorvastatin calcium trihydrate | Tablet, film coated | 13.88 mg~10.844 mg | Resolved | Available | Manufacturing | 26/11/2025 |
| midazolam | Injection, solution | 50 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| flecainide acetate | Tablet, uncoated | 50 mg | Current | Limited Availability | Manufacturing | 26/11/2025 |
| rosuvastatin calcium | Tablet, film coated | 20.84 mg | Current | Unavailable | Unexpected increase in consumer demand | 26/11/2025 |
| pregabalin | Capsule, hard | 150 mg | Current | Limited Availability | Unexpected increase in consumer demand | 26/11/2025 |
| pregabalin | Capsule, hard | 25 mg | Resolved | Available | Manufacturing | 26/11/2025 |
| levetiracetam | Solution | 100 mg/mL | Current | Limited Availability | Manufacturing | 26/11/2025 |
| atomoxetine hydrochloride | Capsule, hard | 20.57 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| dabigatran etexilate mesilate | Capsule, hard | 172.95 mg | Current | Unavailable | Manufacturing | 26/11/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 26/11/2025 |
| tamoxifen citrate | Tablet | 30.34 mg | Anticipated | Available | Manufacturing | 26/11/2025 |
| sunitinib | Capsule | 12.5 mg | Anticipated | Available | Manufacturing | 26/11/2025 |
| tofacitinib citrate | Solution | 1.62 mg/mL | Anticipated | Available | Manufacturing | 26/11/2025 |
| risperidone | Oral Liquid, solution | 1 mg/mL | Current | Unavailable | Manufacturing | 26/11/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 26/11/2025 |
| vinorelbine tartrate | Injection, concentrated | 13.85 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 26/11/2025 |
| vinorelbine tartrate | Injection, concentrated | 13.85 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 26/11/2025 |
| clonidine hydrochloride | Tablet, uncoated | 150 microgram | Anticipated | Available | Manufacturing | 26/11/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 20 mg | Current | Limited Availability | Manufacturing | 26/11/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Current | Limited Availability | Manufacturing | 26/11/2025 |
| flecainide acetate | Injection, solution | 10 mg/mL | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 25/11/2025 |
| lidocaine hydrochloride | Gel | 20 mg/g | Resolved | Available | Manufacturing | 25/11/2025 |
| medronic acid | Injection, powder for | 10 mg | Current | Unavailable | Manufacturing | 25/11/2025 |
| sodium fluoride | Injection, concentrated | 1 mg/mL | Current | Unavailable | Manufacturing | 25/11/2025 |
| phenoxymethylpenicillin potassium | Tablet, film coated | 560 mg | Resolved | Available | Manufacturing | 25/11/2025 |
| armodafinil | Tablet, uncoated | 150 mg | Anticipated | Available | Transport / Logistic issues / Storage capacity issues | 25/11/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Unexpected increase in consumer demand | 25/11/2025 |
| enalapril maleate | Tablet | 5 mg | Anticipated | Available | Manufacturing | 24/11/2025 |
| phenobarbital | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| hydrochlorothiazide~candesartan cilexetil | Tablet, uncoated | 12.5 mg~16 mg | Anticipated | Available | Manufacturing | 24/11/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| nizatidine | Capsule, hard | 150 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Resolved | Available | Unexpected increase in consumer demand | 24/11/2025 |
| ondansetron hydrochloride dihydrate | Tablet, film coated | 9.972 mg | Anticipated | Available | Manufacturing | 24/11/2025 |
| fenofibrate | Tablet, film coated | 145 mg | Anticipated | Available | Manufacturing | 24/11/2025 |
| escitalopram oxalate | Tablet, film coated | 12.74 mg | Resolved | Available | Commercial Changes / Commercial viability | 24/11/2025 |
| escitalopram oxalate | Tablet, film coated | 25.47 mg | Resolved | Available | Manufacturing | 24/11/2025 |
| eplerenone | Tablet, film coated | 25 mg | Current | Limited Availability | Manufacturing | 24/11/2025 |
| Rabies virus | Injection, powder for | 2.5 IU | Resolved | Available | Unexpected increase in consumer demand | 24/11/2025 |
| metaraminol tartrate | Injection, solution | 19 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| Tocilizumab | Injection, solution | 162 mg | Resolved | Available | Manufacturing | 24/11/2025 |
| lanreotide acetate | Injection, solution | 66.67 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 24/11/2025 |
| hydrocortisone hydrogen succinate | Injection, powder for | 127.6 mg | Current | Limited Availability | Manufacturing | 24/11/2025 |
| mupirocin | Ointment | 20 mg/g | Current | Unavailable | Manufacturing | 24/11/2025 |
| labetalol hydrochloride | Tablet, film coated | 100 mg | Current | Unavailable | Manufacturing | 24/11/2025 |
| flunitrazepam | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 24/11/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 582.21 mg | Anticipated | Available | Manufacturing | 24/11/2025 |
| nizatidine | Capsule, hard | 300 mg | Current | Limited Availability | Manufacturing | 24/11/2025 |
2025年12月1日